HRP20220080T1 - Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin - Google Patents
Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin Download PDFInfo
- Publication number
- HRP20220080T1 HRP20220080T1 HRP20220080TT HRP20220080T HRP20220080T1 HR P20220080 T1 HRP20220080 T1 HR P20220080T1 HR P20220080T T HRP20220080T T HR P20220080TT HR P20220080 T HRP20220080 T HR P20220080T HR P20220080 T1 HRP20220080 T1 HR P20220080T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- immunoglobulin variable
- variable domain
- amino acid
- single immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (21)
1. Jednostruka imunoglobulinska varijabilna domena koja se veže na serumski albumin koja sadrži:
(a) CDR1 prema Abm koja je odabrana od sljedećih sekvenci: GFTFSTGEMA (SEQ ID NO: 8) i GFTFDTSSML (SEQ ID NO:13) i koja je poželjno GFTFDTSSML (SEQ ID NO:13); i
(b) CDR2 prema Abm koja je odabrana od sljedećih sekvenci: SISSSGATTY (SEQ ID NO:9) i VIHQSGTPTY (SEQ ID NO:14) i koja je poželjno VIHQSGTPTY (SEQ ID NO:14); i
(c) CDR3 prema Abm koja je odabrana od sljedećih sekvenci: PRHPQGGVTFDY (SEQ ID NO:7), FPSTHGKFDY (SEQ ID NO: 12) i FPSSRMKFDY (SEQ ID NO: 15) i koja je poželjno FPSTHGKFDY (SEQ ID NO: 12) ili FPSSRMKFDY (SEQ ID NO: 15) i koja je najpoželjnije FPSSRMKFDY (SEQ ID NO: 15);
pri čemu navedena jednostruka imunoglobulinska varijabilna domena ima
ne više od 7, kao što je ne više od 5, poželjno ne više od 3, kao što je samo 3, 2 ili 1 aminokiselinskih razlika u okvirima u usporedbi sa sekvencom aminokiseline iz SEQ ID NO: 1, ne uzimajući u obzir mutacije na položaju(ima) 11, 89, 110 ili 112 prema Kabatu koje mogu biti prisutne i ne uzimajući u obzir bilo koje C-terminalno proširenje koje može biti prisutno;
u kojoj:
- aminokiselinski ostatak na položaju 11 je poželjno odabran od L ili V; i
- aminokiselinski ostatak na položaju 89 je poželjno prikladno odabran od T, V ili L; i
- aminokiselinski ostatak na položaju 110 je poželjno prikladno odabran od T, K ili Q; i
- aminokiselinski ostatak na položaju 112 je poželjno prikladno odabran od S, K ili Q;
tako da
(i) položaj 89 je T; ili
(ii) položaj 89 je L i položaj 11 je V; ili
(iii) položaj 89 je L i položaj 110 je K ili Q; ili
(iv) položaj 89 je L i položaj 112 je K ili Q; ili
(v) položaj 89 je L i položaj 11 je V i položaj 110 je K ili Q; ili
(vi) položaj 89 je L i položaj 11 je V i položaj 112 je K ili Q; ili
(vii) položaj 11 je V i položaj 110 je K ili Q; ili
(viii) položaj 11 je V i položaj 112 je K ili Q; i
pri čemu navedena jednostruka imunoglobulinska varijabilna domena ima smanjeno vezanje s već postojećim protutijelima prisutnim u serumu pacijenata sa SLE u usporedbi sa SEQ ID NO: 1.
2. Jednostruka imunoglobulinska varijabilna domena prema patentnom zahtjevu 1, naznačena time što ima C-terminalno proširenje (X)n, u kojem n je 1 do 10, poželjno 1 do 5, kao što je 1, 2, 3, 4 ili 5 (i poželjno 1 ili 2, kao što je 1); a svaki X je (poželjno prirodno prisutan) aminokiselinski ostatak koji se neovisno bira, te je poželjno neovisno odabran iz skupine koju čine alanin (A), glicin (G), valin (V), leucin (L) ili izoleucin (I).
3. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačena time što ima D i/ili E1D mutaciju na položaju 1.
4. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time što ima:
- CDR1 prema Abm koja je GFTFDTSSML (SEQ ID NO: 13); i
- CDR2 prema Abm koja je VIHQSGTPTY (SEQ ID NO:14); i
- CDR3 prema Abm koja je odabrana od sljedećih sekvenci: FPSTHGKFDY (SEQ ID NO: 12) ili FPSSRMKFDY (SEQ ID NO: 15) i koja je poželjno FPSSRMKFDY (SEQ ID NO: 15).
5. Jednostruka imunoglobulinska varijabilna domena prema patentnom zahtjevu 4, naznačena time što ima:
- CDR1 prema Abm koja je GFTFDTSSML (SEQ ID NO: 13); i
- CDR2 prema Abm koja je VIHQSGTPTY (SEQ ID NO:14); i
- CDR3 prema Abm koja je FPSSRMKFDY (SEQ ID NO: 15).
6. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 do 5, naznačena time što ima:
- ne više od 5 aminokiselinskih razlika u okvirima u usporedbi sa sekvencom aminokiseline iz SEQ ID NO: 1, ne uzimajući u obzir bilo koje mutacije na položaju(ima) 11, 89, 110 ili 112 koje mogu biti prisutne i ne uzimajući u obzir bilo koje C-terminalno proširenje koje može biti prisutno.
7. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 do 6, koja sadrži sljedeće aminokiselinske ostatke:
- 11V u kombinaciji s 89L; ili
- 11V u kombinaciji s 110K ili 110Q;
- 11V u kombinaciji s 112K ili 112Q;
- 11V u kombinaciji s 89L i 110K ili 110Q; ili
- 11V u kombinaciji s 89L i 112K ili 112Q.
8. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 do 7, koja sadrži sljedeće aminokiselinske ostatke:
- 89L u kombinaciji s 11V; ili
- 89L u kombinaciji s 110K ili 110Q; ili
- 89L u kombinaciji s 112K ili 112Q; ili
- 89L u kombinaciji s 11V i 110K ili 110Q; ili
- 89L u kombinaciji s 11V i 112K ili 112Q.
9. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 do 7, koja sadrži sljedeće aminokiselinske ostatke:
- 110K ili 110Q u kombinaciji s 11V; ili
- 110K ili 110Q u kombinaciji s 89L; ili
- 110K ili 110Q u kombinaciji s 11V i 89L.
10. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 do 7, koja sadrži sljedeće aminokiselinske ostatke:
- 112K ili 112Q u kombinaciji s 11V; ili
- 112K ili 112Q u kombinaciji s 89L; ili
- 112K ili 112Q u kombinaciji s 11V i 89L.
11. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1 do 7, koja sadrži sljedeći aminokiselinski ostatak:
- 89T.
12. Jednostruka imunoglobulinska varijabilna domena prema patentnom zahtjevu 1, naznačena time što ima sekvencu aminokiseline koja je odabrana od sekvenci aminokiselina prema SEQ ID NO: 16 do 99.
13. Jednostruka imunoglobulinska varijabilna domena prema patentnom zahtjevu 12, naznačena time što ima sekvencu aminokiseline koja je odabrana od sekvenci aminokiselina prema SEQ ID NO: 44 do 99.
14. Jednostruka imunoglobulinska varijabilna domena prema patentnom zahtjevu 13, naznačena time što ima sekvencu aminokiseline koja je jedna od slijedećih sekvenci: SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98 ili SEQ ID NO:99.
15. Jednostruka imunoglobulinska varijabilna domena prema patentnom zahtjevu 13, naznačena time što ima sekvencu aminokiseline koja je jedna od slijedećih sekvenci: SEQ ID NO: 50, SEQ ID NO: 64, SEQ ID NO: 78 ili SEQ ID NO: 92, i poželjno SEQ ID NO: 78 ili SEQ ID NO: 92.
16. Protein, polipeptid, konstrukt, molekula ili kemijski entitet koji sadrži jednu ili više jednostrukih imunoglobulinskih varijabilnih domena prema bilo kojem od patentnih zahtjeva 1 do 15.
17. Nukleinska kiselina naznačena time što kodira jednostruku imunoglobulinsku varijabilnu domenu prema bilo kojem od patentnih zahtjeva 1-15 i/ili protein ili polipeptid prema patentnom zahtjevu 16.
18. Ne-ljudski domaćin ili stanica domaćin koja sadrži nukleinsku kiselinu prema patentnom zahtjevu 17, i/ili koja eksprimira jednostruku imunoglobulinsku varijabilnu domenu prema bilo kojem od patentnih zahtjeva 1-15, ili polipeptid prema patentnom zahtjevu 16.
19. Postupci za pripravu imunoglobulinske varijabilne domene prema bilo kojem od patentnih zahtjeva 1-15 i/ili polipeptida prema patentnom zahtjevu 16, naznačeni time što obuhvaćaju kultiviranje ili održavanje stanice domaćina prema patentnom zahtjevu 18 pod uvjetima u kojima navedena stanica domaćin proizvodi ili eksprimira imunoglobulinsku varijabilnu domenu ili polipeptid, te po izboru izoliranje tako dobivene imunoglobulinske varijabilne domene ili polipeptida.
20. Pripravak ili proizvod koji sadrži jednostruku imunoglobulinsku varijabilnu domenu prema bilo kojem od patentnih zahtjeva 1-15 i/ili protein, polipeptid, konstrukt, molekulu ili kemijski entitet prema patentnom zahtjevu 16.
21. Jednostruka imunoglobulinska varijabilna domena prema bilo kojem od patentnih zahtjeva 1-15 ili protein, polipeptid, konstrukt, molekula ili kemijski entitet prema patentnom zahtjevu 16 za upotrebu u terapiji.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254813P | 2015-11-13 | 2015-11-13 | |
| EP16790934.0A EP3374392B1 (en) | 2015-11-13 | 2016-10-28 | Improved serum albumin-binding immunoglobulin variable domains |
| PCT/EP2016/076088 WO2017080850A1 (en) | 2015-11-13 | 2016-10-28 | Improved serum albumin-binding immunoglobulin variable domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220080T1 true HRP20220080T1 (hr) | 2022-04-15 |
Family
ID=57233415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220080TT HRP20220080T1 (hr) | 2015-11-13 | 2016-10-28 | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11142569B2 (hr) |
| EP (2) | EP3974449A1 (hr) |
| JP (2) | JP7195142B2 (hr) |
| CN (2) | CN108290943A (hr) |
| AU (1) | AU2016351710B2 (hr) |
| DK (1) | DK3374392T3 (hr) |
| ES (1) | ES2905912T3 (hr) |
| HR (1) | HRP20220080T1 (hr) |
| HU (1) | HUE057241T2 (hr) |
| LT (1) | LT3374392T (hr) |
| PL (1) | PL3374392T3 (hr) |
| PT (1) | PT3374392T (hr) |
| RS (1) | RS62857B1 (hr) |
| SI (1) | SI3374392T1 (hr) |
| WO (1) | WO2017080850A1 (hr) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| SG10201805064SA (en) | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| IL318433A (en) | 2014-05-16 | 2025-03-01 | Ablynx Nv | Improved immunoglobulin variable complexes |
| EP4707303A2 (en) | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| LT3374392T (lt) * | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
| JP7219220B2 (ja) * | 2017-01-17 | 2023-02-07 | アブリンクス エン．ヴェー． | 改善された血清アルブミン結合剤 |
| TW202417517A (zh) | 2017-06-02 | 2024-05-01 | 德商麥克專利有限公司 | 與ｍｍｐ１３結合之免疫球蛋白 |
| JP7249961B2 (ja) | 2017-06-02 | 2023-03-31 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ａｄａｍｔｓ５、ｍｍｐ１３およびアグリカンに結合するポリペプチド |
| CN113508134B (zh) * | 2019-02-22 | 2024-12-03 | 安维达生物科技公司 | 白蛋白结合抗体及其用途 |
| TWI844709B (zh) | 2019-07-31 | 2024-06-11 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
| KR20220111313A (ko) | 2019-12-06 | 2022-08-09 | 아블린쓰 엔.브이. | TNFα 및 OX40L을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| IL293561A (en) | 2019-12-06 | 2022-08-01 | Ablynx Nv | Polypeptides comprising immunoglobulin with one variable domain targeting TNFa and IL-23 |
| MX2022007035A (es) | 2019-12-09 | 2022-06-23 | Ablynx Nv | Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y tslp. |
| CN115397868A (zh) | 2020-03-30 | 2022-11-25 | 埃博灵克斯股份有限公司 | 用于产生和纯化多价免疫球蛋白单可变域的方法 |
| AU2021350156A1 (en) | 2020-09-25 | 2023-06-08 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| IL303740A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| EP4263602A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| CA3205422A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| KR20240122867A (ko) | 2021-12-17 | 2024-08-13 | 아블린쓰 | TCRαβ, CD33, 및 CD123을 표적화하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| AU2023290487A1 (en) | 2022-06-14 | 2025-01-30 | Ablynx Nv | Immunoglobulin single variable domains targeting t cell receptor |
| US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
| US20250388663A1 (en) * | 2022-08-17 | 2025-12-25 | Institut National de la Santé et de la Recherche Médicale | Improved anti-albumin nanobodies and their uses |
| EP4605077A1 (en) | 2022-10-18 | 2025-08-27 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| AR131494A1 (es) | 2022-12-23 | 2025-03-26 | Ablynx Nv | Vehículos de conjugación a base de proteína |
| JP2026503077A (ja) | 2023-01-09 | 2026-01-27 | オデッセイ セラピューティクス，インコーポレイテッド | 抗ｔｎｆｒ２抗原結合タンパク質及びその使用 |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| TW202444757A (zh) | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| EP4713364A1 (en) | 2023-05-17 | 2026-03-25 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
| EP4731770A1 (en) | 2023-06-22 | 2026-04-29 | Ablynx NV | Chimeric proteins for modulating cytokine receptor activity |
| KR20260032566A (ko) | 2023-06-29 | 2026-03-09 | 오디세이 테라퓨틱스, 인코포레이티드 | 항-trailr2 항원-결합 단백질 및 그의 용도 |
| WO2025008537A1 (en) | 2023-07-05 | 2025-01-09 | Ablynx Nv | Improved fcrn antagonists for treatment of igg-related diseases and disorders |
| WO2025051767A1 (en) | 2023-09-04 | 2025-03-13 | Sanofi | Polypeptides for use in the treatment of glypican-3-expressing tumours |
| TW202532432A (zh) | 2023-09-22 | 2025-08-16 | 比利時商艾伯霖克斯公司 | 二及多價白蛋白結合劑 |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| TW202540169A (zh) | 2023-11-08 | 2025-10-16 | 法商賽諾菲公司 | 基於ｃｄ２５的溶酶體降解物及其用途 |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| WO2025114529A1 (en) | 2023-12-01 | 2025-06-05 | Ablynx Nv | Multispecific antibodies recognising human serum albumin, tcr and a tumor antigen recognising moiety |
| TW202543670A (zh) | 2023-12-22 | 2025-11-16 | 比利時商艾伯霖克斯公司 | 用於核內投予之基於蛋白質的接合載劑 |
| TW202542180A (zh) | 2023-12-22 | 2025-11-01 | 比利時商艾伯霖克斯公司 | 用於位點特異性胺軛合的基於蛋白質的載體 |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
| WO2026006708A2 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| WO2026052756A1 (en) | 2024-09-05 | 2026-03-12 | Ablynx Nv | Her2 binding immunoglobulin single variable domains, constructs comprising the same and uses thereof |
| WO2026078159A1 (en) | 2024-10-10 | 2026-04-16 | Ablynx Nv | Immune cell engagers and methods comprising the same |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| WO2004041863A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against interferon- gamma and uses therefor |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| MX2007006593A (es) | 2004-12-02 | 2008-03-04 | Domantis Ltd | Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos. |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| ES2694247T3 (es) | 2005-05-20 | 2018-12-19 | Ablynx N.V. | NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación |
| JP2009519011A (ja) | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| EA200801166A1 (ru) | 2005-12-01 | 2008-12-30 | Домантис Лимитед | Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| US20100047171A1 (en) | 2006-01-24 | 2010-02-25 | Roland Beckmann | Fusion Proteins That Contain Natural Junctions |
| WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| WO2009089295A2 (en) * | 2008-01-07 | 2009-07-16 | Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Anti-hiv domain antibodies and method of making and using same |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| EP2285833B1 (en) | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| US9005963B2 (en) * | 2008-10-14 | 2015-04-14 | Ablynx N.V. | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| WO2011006915A2 (en) * | 2009-07-16 | 2011-01-20 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| EP2571900A1 (en) * | 2010-05-20 | 2013-03-27 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| US9012609B2 (en) * | 2010-08-13 | 2015-04-21 | Glaxosmithkline Intellectual Property Development Limited | Anti-serum albumin binding variants |
| WO2012072731A2 (en) | 2010-12-01 | 2012-06-07 | Glaxo Group Limited | Improved anti-serum albumin binding single variable domains |
| WO2012093125A1 (en) * | 2011-01-06 | 2012-07-12 | Glaxo Group Limited | Ligands that bind tgf-beta receptor ii |
| CN103917560B (zh) * | 2011-03-28 | 2017-05-24 | 埃博灵克斯股份有限公司 | 双特异性抗‑cxcr7免疫球蛋白单可变结构域 |
| US9527925B2 (en) * | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| EP2723771B1 (en) * | 2011-06-23 | 2019-09-11 | Ablynx NV | Serum albumin binding proteins |
| SG10201805064SA (en) * | 2011-06-23 | 2018-07-30 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| WO2014111550A1 (en) * | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| EP4707303A2 (en) * | 2014-05-16 | 2026-03-11 | Ablynx NV | Improved immunoglobulin variable domains |
| LT3374392T (lt) * | 2015-11-13 | 2022-01-25 | Ablynx Nv | Patobulinti serumo albuminą surišantys imunoglobulino kintami domenai |
-
2016
- 2016-10-28 LT LTEPPCT/EP2016/076088T patent/LT3374392T/lt unknown
- 2016-10-28 ES ES16790934T patent/ES2905912T3/es active Active
- 2016-10-28 US US15/769,800 patent/US11142569B2/en active Active
- 2016-10-28 RS RS20220086A patent/RS62857B1/sr unknown
- 2016-10-28 HU HUE16790934A patent/HUE057241T2/hu unknown
- 2016-10-28 HR HRP20220080TT patent/HRP20220080T1/hr unknown
- 2016-10-28 PT PT167909340T patent/PT3374392T/pt unknown
- 2016-10-28 CN CN201680066246.6A patent/CN108290943A/zh active Pending
- 2016-10-28 EP EP21197952.1A patent/EP3974449A1/en active Pending
- 2016-10-28 WO PCT/EP2016/076088 patent/WO2017080850A1/en not_active Ceased
- 2016-10-28 JP JP2018524454A patent/JP7195142B2/ja active Active
- 2016-10-28 DK DK16790934.0T patent/DK3374392T3/da active
- 2016-10-28 EP EP16790934.0A patent/EP3374392B1/en active Active
- 2016-10-28 CN CN202210797845.2A patent/CN115925919A/zh active Pending
- 2016-10-28 PL PL16790934T patent/PL3374392T3/pl unknown
- 2016-10-28 AU AU2016351710A patent/AU2016351710B2/en active Active
- 2016-10-28 SI SI201631451T patent/SI3374392T1/sl unknown
-
2021
- 2021-09-22 US US17/481,578 patent/US20220112275A1/en active Pending
-
2022
- 2022-12-13 JP JP2022198469A patent/JP7840836B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7195142B2 (ja) | 2022-12-23 |
| US20180312578A1 (en) | 2018-11-01 |
| AU2016351710A1 (en) | 2018-05-10 |
| WO2017080850A1 (en) | 2017-05-18 |
| LT3374392T (lt) | 2022-01-25 |
| US11142569B2 (en) | 2021-10-12 |
| JP7840836B2 (ja) | 2026-04-06 |
| AU2016351710B2 (en) | 2023-08-03 |
| ES2905912T3 (es) | 2022-04-12 |
| JP2019502656A (ja) | 2019-01-31 |
| HUE057241T2 (hu) | 2022-04-28 |
| CN115925919A (zh) | 2023-04-07 |
| CA3005061A1 (en) | 2017-05-18 |
| PT3374392T (pt) | 2022-02-07 |
| US20220112275A1 (en) | 2022-04-14 |
| CN108290943A (zh) | 2018-07-17 |
| RS62857B1 (sr) | 2022-02-28 |
| PL3374392T3 (pl) | 2022-03-28 |
| SI3374392T1 (sl) | 2022-04-29 |
| EP3374392A1 (en) | 2018-09-19 |
| DK3374392T3 (da) | 2022-02-14 |
| EP3374392B1 (en) | 2021-11-24 |
| EP3974449A1 (en) | 2022-03-30 |
| JP2023027258A (ja) | 2023-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220080T1 (hr) | Poboljšane imunoglobulinske varijabilne domene koje vežu serumski albumin | |
| HRP20241469T1 (hr) | Poboljšana veziva albumina u serumu | |
| IL295534A (en) | Improved immunoglobulin variable domains | |
| FI3571224T3 (fi) | Parannettuja seerumialbumiinin sitojia | |
| JP2017512063A5 (hr) | ||
| RU2019120720A (ru) | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином | |
| HRP20231410T1 (hr) | Konstrukti bispecifičnih antitijela koji vežu mezotelin i cd3 | |
| JP2020506898A5 (hr) | ||
| JP2016511277A5 (hr) | ||
| JP2017509335A5 (hr) | ||
| PH12019550087A1 (en) | Anti-cd73 antibodies and uses thereof | |
| JP2020511113A5 (hr) | ||
| JP2020515518A5 (hr) | ||
| PE20181956A1 (es) | Polipeptidos que inhiben cd40l | |
| JP2020500510A5 (hr) | ||
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| RU2019119857A (ru) | Антитела к компоненту комплемента c5 | |
| CN114478753A (zh) | 非免疫原性单结构域抗体 | |
| JP2018502572A5 (hr) | ||
| JP2017529067A5 (hr) | ||
| JP2012514997A5 (hr) | ||
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
| WO2017149394A1 (en) | Non-antagonistic antibodies directed against the alpha chain of the il7 receptor extracellular domain and use thereof in cancer treatment | |
| RU2017106743A (ru) | НОВОЕ АНТИТЕЛО ПРОТИВ Igβ ЧЕЛОВЕКА | |
| CA2965170A1 (en) | Cd83 binding proteins and uses thereof |